| pubmed-article:1350190 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1350190 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:1350190 | lifeskim:mentions | umls-concept:C0034798 | lld:lifeskim |
| pubmed-article:1350190 | lifeskim:mentions | umls-concept:C0040615 | lld:lifeskim |
| pubmed-article:1350190 | lifeskim:mentions | umls-concept:C1521797 | lld:lifeskim |
| pubmed-article:1350190 | lifeskim:mentions | umls-concept:C0205191 | lld:lifeskim |
| pubmed-article:1350190 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:1350190 | pubmed:dateCreated | 1992-6-17 | lld:pubmed |
| pubmed-article:1350190 | pubmed:abstractText | We studied the in vitro electrical activity of rat neostriatal neurons following chronic neuroleptic treatment. In haloperidol-treated rats, unlike naive animals, activation of neostriatal D2 dopamine receptors induced a potent presynaptic inhibition of glutamate-mediated excitatory synaptic potentials. Haloperidol treatment did not affect the intrinsic membrane properties of the neostriatal neurons. Pre- and postsynaptic physiological responses to direct and indirect gamma-aminobutyric acid (GABA)-ergic and cholinergic agonists were not affected by chronic haloperidol treatment. These findings suggest that movement disorders induced by chronic neuroleptic treatment may result, at least in part, from a hypersensitivity of presynaptic D2 dopamine receptors regulating the release of glutamate. | lld:pubmed |
| pubmed-article:1350190 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1350190 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1350190 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1350190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1350190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1350190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1350190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1350190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1350190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1350190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1350190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1350190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1350190 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1350190 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1350190 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:1350190 | pubmed:issn | 0364-5134 | lld:pubmed |
| pubmed-article:1350190 | pubmed:author | pubmed-author:BernardiGG | lld:pubmed |
| pubmed-article:1350190 | pubmed:author | pubmed-author:CalabresiPP | lld:pubmed |
| pubmed-article:1350190 | pubmed:author | pubmed-author:De MurtasMM | lld:pubmed |
| pubmed-article:1350190 | pubmed:author | pubmed-author:MercuriN BNB | lld:pubmed |
| pubmed-article:1350190 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1350190 | pubmed:volume | 31 | lld:pubmed |
| pubmed-article:1350190 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1350190 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1350190 | pubmed:pagination | 366-73 | lld:pubmed |
| pubmed-article:1350190 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1350190 | pubmed:meshHeading | pubmed-meshheading:1350190-... | lld:pubmed |
| pubmed-article:1350190 | pubmed:meshHeading | pubmed-meshheading:1350190-... | lld:pubmed |
| pubmed-article:1350190 | pubmed:meshHeading | pubmed-meshheading:1350190-... | lld:pubmed |
| pubmed-article:1350190 | pubmed:meshHeading | pubmed-meshheading:1350190-... | lld:pubmed |
| pubmed-article:1350190 | pubmed:meshHeading | pubmed-meshheading:1350190-... | lld:pubmed |
| pubmed-article:1350190 | pubmed:meshHeading | pubmed-meshheading:1350190-... | lld:pubmed |
| pubmed-article:1350190 | pubmed:meshHeading | pubmed-meshheading:1350190-... | lld:pubmed |
| pubmed-article:1350190 | pubmed:meshHeading | pubmed-meshheading:1350190-... | lld:pubmed |
| pubmed-article:1350190 | pubmed:meshHeading | pubmed-meshheading:1350190-... | lld:pubmed |
| pubmed-article:1350190 | pubmed:meshHeading | pubmed-meshheading:1350190-... | lld:pubmed |
| pubmed-article:1350190 | pubmed:meshHeading | pubmed-meshheading:1350190-... | lld:pubmed |
| pubmed-article:1350190 | pubmed:meshHeading | pubmed-meshheading:1350190-... | lld:pubmed |
| pubmed-article:1350190 | pubmed:meshHeading | pubmed-meshheading:1350190-... | lld:pubmed |
| pubmed-article:1350190 | pubmed:meshHeading | pubmed-meshheading:1350190-... | lld:pubmed |
| pubmed-article:1350190 | pubmed:meshHeading | pubmed-meshheading:1350190-... | lld:pubmed |
| pubmed-article:1350190 | pubmed:meshHeading | pubmed-meshheading:1350190-... | lld:pubmed |
| pubmed-article:1350190 | pubmed:meshHeading | pubmed-meshheading:1350190-... | lld:pubmed |
| pubmed-article:1350190 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1350190 | pubmed:articleTitle | Chronic neuroleptic treatment: D2 dopamine receptor supersensitivity and striatal glutamatergic transmission. | lld:pubmed |
| pubmed-article:1350190 | pubmed:affiliation | Clinica Neurologica, Dip. Sanità, II Università degli Studi di Roma, Italy. | lld:pubmed |
| pubmed-article:1350190 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1350190 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1350190 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1350190 | lld:pubmed |
